Clinical Trials Logo

Filter by:
NCT ID: NCT02119663 Terminated - Pancreatic Cancer Clinical Trials

A Study of Ruxolitinib in Pancreatic Cancer Patients

Start date: June 2014
Phase: Phase 3
Study type: Interventional

This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.

NCT ID: NCT02080364 Terminated - Alzheimer's Disease Clinical Trials

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

STEADFAST
Start date: April 2015
Phase: Phase 3
Study type: Interventional

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

NCT ID: NCT02050997 Terminated - Clinical trials for Pancreatic Ductal Adenocarcinoma

Plasma Biomarkers P-DAC, V1

Start date: May 26, 2014
Phase:
Study type: Observational

This is an exploratory, translational, non-interventional and multi-centre clinical study. The aim of the study is to identify predictive plasma biomarkers of response to chemotherapy in PDAC.

NCT ID: NCT02050737 Terminated - Colorectal Cancer Clinical Trials

Plasma Biomarkers C-RAC, ICORG 12-27, V1

Start date: October 2013
Phase:
Study type: Observational

This is an exploratory, translational, non-interventional and multi-centre clinical study.

NCT ID: NCT02013167 Terminated - Clinical trials for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: January 3, 2014
Phase: Phase 3
Study type: Interventional

The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.

NCT ID: NCT01975389 Terminated - Clinical trials for Cardiovascular Disease

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

SPIRE-2
Start date: October 29, 2013
Phase: Phase 3
Study type: Interventional

This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization in high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C >/= 100 mg/dL (2.6 mmol/L) or non-HDL-C >/=130 mg/dL (3.4 mmol/L).

NCT ID: NCT01975376 Terminated - Clinical trials for Cardiovascular Disease

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

SPIRE-1
Start date: October 29, 2013
Phase: Phase 3
Study type: Interventional

This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization, in high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C >/= 70 mg/dL (1.8 mmol/L) or non-HDL-C >/= 100 mg /dL (2.6 mmol/L).

NCT ID: NCT01965314 Terminated - Clinical trials for Anesthesiology Training

A Trial to Determine the Effect of Simulation Based Training on Initial Performance of Ultrasound Guided Axillary Brachial Plexus Blockade in a Clinical Setting

Start date: July 2010
Phase: N/A
Study type: Interventional

Investigators hypothesize that virtual reality based training offers an additional learning benefit over standard training (using cadaveric dissection and human volunteers) in preparing novice anaesthetists to perform their first Ultrasound guided Axillary Brachial Plexus Blockade (USgABPB) in the clinical setting. Investigators hope that this body of work will aid the development of a visuo-haptic simulator used to improved training of doctors in performing USgABPB. Ultimately any patient having this procedure carried out in the future should benefit. In particular it will avoid the need for novice trainees to practice new techniques on patients.

NCT ID: NCT01953926 Terminated - Clinical trials for Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

SUMMIT
Start date: September 30, 2013
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.

NCT ID: NCT01902290 Terminated - Asthma Clinical Trials

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Start date: May 22, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.